Expert Discusses Quality Standards' Role in the Evolution of Biosimilars and Biologics Landscape
February 13th 2024Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses how established quality standards, drawing from the realm of small molecule drugs and evolving to meet the complexities of biologics, play a pivotal role in fostering trust.
Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
February 12th 2024Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.
Implementing Bispecific Antibodies in Lymphoma Care
February 9th 2024Experts provide practical guidelines and key takeaways for health care professionals and policymakers on the implementation of bispecific antibodies in DLBCL (diffuse large B cell lymphoma), emphasizing safety, efficacy, and operational strategies.
Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
February 7th 2024Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.
Key Considerations in Treatment Selection for Patients With Multiple Myeloma
January 29th 2024Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.
Role of the Oncology Pharmacists Is ‘On the Cusp of Beginning to Evolve and Change’
January 26th 2024Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.
Multidisciplinary Bispecific Care
January 26th 2024Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.